PF 6751979

Drug Profile

PF 6751979

Alternative Names: PF-06751979

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antidementias
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 01 Jan 2017 Pfizer completes a phase I trial in Alzheimer's disease (In adults, In the elderly, In volunteers) in Belgium (PO) (NCT02793232)
  • 18 Jul 2016 Pfizer completes a phase I trial in Alzheimer's disease (In volunteers) in USA (NCT02509117)
  • 03 Jun 2016 Pfizer plans a phase I trial in Healthy volunteers in Belgium (NCT02793232)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top